Intravenous Infusion of CAP-1002 in Patients With COVID-19

Summary

This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.

Timeline

Start

2020-11-15

Primary completion

2022-02-04

Completion

2022-02-04

Drugs

Indications